News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Triphase Receives FDA Orphan Drug Designation For Marizomib In Multiple Myeloma


2/27/2014 10:45:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES